Stefania Re Depaolini

The target landscape of clinical kinase drugs

Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm et al. · Science · 2017 · 845 citations · Full text

Tumor Biology, Proteomicsdb Database, Drug Target +14

Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase

Riccardo Colombo, Marina Caldarelli, Milena Mennecozzi et al. · Cancer Research · 2010 · 199 citations · Full text

Cancer Therapy, Mitotic Checkpoint, Mps1 Kinase +14

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

Italo Beria, R Bossi, Maria Gabriella Brasca et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 104 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +9

Structural Insight into Maternal Embryonic Leucine Zipper Kinase (MELK) Conformation and Inhibition toward Structure-Based Drug Design

Giulia Canevari, Stefania Re Depaolini, Ulisse Cucchi et al. · Biochemistry · 2013 · 30 citations

Drug Target, Molecular Biology, Structural Insight +16

Identification of candidate substrates for poly(ADP‐ribose) polymerase‐2 (PARP2) in the absence of DNA damage using high‐density protein microarrays

Sonia Troiani, Rosita Lupi, Rita Perego et al. · FEBS Journal · 2011 · 29 citations · Full text

Dna Damage, Dna Microarrays, Molecular Biology +16